← All trials
NCT03732703
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2019
- Primary completion
- Feb 10, 2022
- Completion date
- Feb 10, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 228
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Multiple Myeloma Research ConsortiumLead sponsor
- CelgeneCollaborator
- Eli LillyCollaborator
- Janssen Pharmaceutica NVCollaborator
- AbbVieCollaborator
- TakedaCollaborator
- GenentechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.